Cellectis to Report First Quarter 2022 Financial Results
Published on May 05, 2022 in New York, NY
New York, NY – May 5, 2022 – Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter ended March 31st, 2022, on Thursday, May 12th, 2022, after the close of the US market.
The announcement will be followed by a conference call and live audio webcast on Friday, May 13th, 2022, at 8:00 AM EDT / 2:00 PM CET. The call will include the Company’s first quarter results and an update on business activities. Details for the call are as follows:
Dial In Information: Friday, May 13th, 8:00 AM EDT / 2:00 PM CET
Conference ID: 13728396
Webcast link: https://viavid.webcasts.com/starthere.jsp?ei=1539526&tp_key=3126715663